I-Mab Stock Forecast, Price & News

-1.26 (-1.69 %)
(As of 06/18/2021 04:30 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume692,848 shs
Average Volume467,165 shs
Market Capitalization$5.32 billion
P/E Ratio69.25
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

I-Mab logo

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.09 out of 5 stars

Medical Sector

1049th out of 2,100 stocks

Pharmaceutical Preparations Industry

497th out of 831 stocks

Analyst Opinion: 1.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

I-Mab (NASDAQ:IMAB) Frequently Asked Questions

Is I-Mab a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" I-Mab stock.
View analyst ratings for I-Mab
or view top-rated stocks.

What stocks does MarketBeat like better than I-Mab?

Wall Street analysts have given I-Mab a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but I-Mab wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting I-Mab?

I-Mab saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 1,980,000 shares, an increase of 39.4% from the May 13th total of 1,420,000 shares. Based on an average trading volume of 551,700 shares, the days-to-cover ratio is currently 3.6 days.
View I-Mab's Short Interest

How has I-Mab's stock price been impacted by Coronavirus?

I-Mab's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMAB shares have increased by 436.6% and is now trading at $73.08.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IMAB?

5 brokerages have issued twelve-month price objectives for I-Mab's shares. Their forecasts range from $75.00 to $90.00. On average, they expect I-Mab's share price to reach $78.75 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts' price targets for I-Mab
or view top-rated stocks among Wall Street analysts.

Who are I-Mab's key executives?

I-Mab's management team includes the following people:
  • Dr. Jingwu Zhang Zang M.D., Ph.D., Founder & Chairman (Age 65)
  • Dr. Joan Huaqiong Shen M.D., Ph.D., CEO & Director (Age 59)
  • Dr. Zheru Zhang Ph.D., Pres & Director (Age 58)
  • Mr. Jielun Zhu, CFO & Director (Age 45)
  • Dr. Lili Qian Ph.D., VP of Operations (Age 39)
  • Ms. Leah Liu, Sr. IR Director
  • Mr. Cheng Li, Chief Legal Officer (Age 37)
  • Ms. Gigi Qi Feng, Chief Communications Officer (Age 40)
  • Dr. Yunhan Lin Ph.D., VP of Corp. Devel. (Age 44)
  • Dr. Weiming Tang Ph.D., Exec. VP of Global Bus. Devel. (Age 56)

Who are some of I-Mab's key competitors?

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ).

When did I-Mab IPO?

(IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

What is I-Mab's stock symbol?

I-Mab trades on the NASDAQ under the ticker symbol "IMAB."

Who are I-Mab's major shareholders?

I-Mab's stock is owned by many different institutional and retail investors. Top institutional investors include Hillhouse Capital Advisors LTD. (9.14%), Cederberg Capital Ltd (2.94%), Ward Ferry Management BVI Ltd (2.49%), Artisan Partners Limited Partnership (1.22%), The Manufacturers Life Insurance Company (1.03%) and Price T Rowe Associates Inc. MD (0.95%).

Which institutional investors are selling I-Mab stock?

IMAB stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sphera Funds Management LTD., Citadel Advisors LLC, Renaissance Technologies LLC, Bellevue Group AG, and Vident Investment Advisory LLC.

Which institutional investors are buying I-Mab stock?

IMAB stock was acquired by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Cederberg Capital Ltd, Ward Ferry Management BVI Ltd, Price T Rowe Associates Inc. MD, Ghisallo Capital Management LLC, Indus Capital Partners LLC, E Fund Management Co. Ltd., and Millennium Management LLC.

How do I buy shares of I-Mab?

Shares of IMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is I-Mab's stock price today?

One share of IMAB stock can currently be purchased for approximately $73.08.

How much money does I-Mab make?

I-Mab has a market capitalization of $5.29 billion and generates $236.42 million in revenue each year. The company earns $72.17 million in net income (profit) each year or $1.06 on an earnings per share basis.

How many employees does I-Mab have?

I-Mab employs 228 workers across the globe.

What is I-Mab's official website?

The official website for I-Mab is

Where are I-Mab's headquarters?


How can I contact I-Mab?

I-Mab's mailing address is SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6057-8000 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.